Acumen Pharmaceuticals, Inc.
ABOS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001576885
No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 41 | 1 | 52 | +12 |
| Shares | 24.1M | 153.9K | 25.6M | +1.69M (+7.1%) |
| Value | $357.4M | $2.29M | $172.9M | −$182.1M (−51.3%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deep Track Capital, LP | 1,933,040 | $13.1M | 0.97% |
| Schonfeld Strategic Advisors LLC | 86,543 | $585.0K | 0.01% |
| HRT Financial LP | 81,917 | $553.0K | 0.00% |
| Ergoteles LLC | 77,152 | $522.0K | 0.02% |
| Rex Capital Advisors, LLC | 65,336 | $442.0K | 0.23% |
| Millennium Management LLC | 37,163 | $251.0K | 0.00% |
| Renaissance Technologies LLC | 21,609 | $146.0K | 0.00% |
| Jump Financial, LLC | 20,097 | $136.0K | 0.01% |
| Squarepoint Ops LLC | 18,818 | $127.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 11,545 | $78.0K | 0.00% |
| New York State Common Retirement Fund | 5,481 | $37.0K | 0.00% |
| Bedel Financial Consulting, Inc. | 240 | $2.00K | 0.00% |
| FinTrust Capital Advisors, LLC | 20 | $0 | 0.00% |
Sold out (1)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Captrust Financial Advisors | 78 | $1.00K |
Not filed for Q4 2021 yet (1)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 153,908 | $2.29M |